Overview

Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects

Status:
Completed

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

Summary

To evaluate the pharmacokinetic (PK) characteristics after multiple oral administration of 40 mg lurasidone in healthy Chinese subjects. To evaluate the safety and tolerance after multiple oral administration of 40 mg lurasidone in healthy Chinese subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Sumitomo Pharmaceutical (Suzhou) Co., Ltd.

Collaborator:

Xuhui Central Hospital, Shanghai

Treatments:

Lurasidone Hydrochloride